{"id":15222,"date":"2021-12-15T15:36:10","date_gmt":"2021-12-15T15:36:10","guid":{"rendered":"https:\/\/interhospi.com\/?p=15222"},"modified":"2021-12-21T12:27:11","modified_gmt":"2021-12-21T12:27:11","slug":"who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology","status":"publish","type":"post","link":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/","title":{"rendered":"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology"},"content":{"rendered":"<div id='av_section_1'  class='avia-section main_color avia-section-default avia-no-border-styling  avia-bg-style-scroll  avia-builder-el-0  avia-builder-el-no-sibling   container_wrap fullsize' style=' '  ><div class='container' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-15222'><div class='entry-content-wrapper clearfix'>\n<div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding first  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><\/div><div class=\"flex_column av_three_fifth  flex_column_div av-zero-column-padding   avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><header class=\"entry-content-header\"><h1 class=\"post-title entry-title\" itemprop=\"headline\">WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology<\/h1><span class=\"post-meta-infos\">\/ <span class=\"blog-categories minor-meta\">in <a href=\"https:\/\/interhospi.com\/category\/e-news\/\" rel=\"tag\">E-News<\/a>  <\/span><\/span><\/header>\n<\/div><\/section><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p><strong>WHO\u2019s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) have finalized a licensing agreement with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody technology. The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine. This represents the first transparent, global, non-exclusive licence for a COVID-19 health tool, and the first test licence signed by MPP and included in the WHO Pool.<\/strong><\/p>\n<p><!--more--><\/p>\n<p>The aim of the licence is to facilitate the rapid manufacture and commercialization of CSIC\u2019s COVID-19 serological test world- wide. The agreement covers all related patents and the biological material necessary for manufacture of the test. CSIC will provide all know-how to MPP and\/or to prospective licensees as well as training. The licence will be royalty-free for low- and middle-income countries and will remain valid until the date the last patent expires.<\/p>\n<p>\u201cThis licence is a testament to what we can achieve when putting people at the centre of our global and multilateral efforts,\u201d said Carlos Alvarado Quesada, President of Costa Rica, the founding country of C-TAP. \u201cIt shows that solidarity and equitable access can be achieved and that it is worthwhile continuing to support the principles of transparency, inclusiveness and non-exclusivity that the C-TAP defends. Costa Rica welcomes the signing of this licence and is convinced, today more than ever, that mechanisms such as C-TAP can help us overcome the current situation, while being beneficial for future health crises. I thank the Spanish Government and CSIC, for taking a step forward in solidarity and prioritizing health as a global public good.\u201d<\/p>\n<p>\u201cI highly commend CSIC, a public research institute, for its commitment to solidarity and for offering worldwide access to their technology and know-how,\u201d said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. \u201cThis is the kind of open and transparent licence we need to move the needle on access during and after the pandemic. I urge developers of COVID-19 vaccines, treatments and diagnostics to follow this example and turn the tide on the pandemic and on the devastating global inequity this pandemic has spotlighted.\u201d<\/p>\n<p>\u201cOur strong partnership with WHO and C-TAP partners has been essential in negotiating this licence, and I look forward to our continued collaboration, drawing on WHO\u2019s expertise and guidance going forward,\u201d said Charles Gore, Executive Director of MPP. \u201cWhat is clear is that MPP\u2019s model can work across different health technologies, and we are thrilled to be signing our first C-TAP\/MPP test licence with CSIC.\u201d<\/p>\n<p>Dr Rosa Men\u00e9ndez, president of CSIC, emphasized how important it is to seek solutions so that technologies related to the COVID-19 pandemic in particular, and health in general, reach all countries, including those most in need. \u201cIn this sense, we would like this action by CSIC, of taking part in the international initiatives of MPP and WHO, to become an example and a reference for other research organizations in the world.\u201d<\/p>\n<p>The technology to date has resulted in four different tests, one of which has the potential to distinguish the immune response of COVID-19 infected individuals from vaccinated individuals. This should aid further research into the level and length of immunity and the efficacy of the tools at our disposal.<\/p>\n<p>The tests are simple to use and suitable for all settings with a basic laboratory infrastructure, such as those found in rural areas in low- and middle-income countries. The reading can theoretically be done manually (with naked eye comparing the colour of the wells against the colour chart), but an ELISA reader is recommended for greater accuracy of results.<\/p>\n<p>Promising performance data in the European population will need to be supplemented by the companies that will produce this technology if they plan to sell the test in low- and middle-income countries.<\/p>\n<\/div><\/section><br \/>\n<div  style='height:50px' class='hr hr-invisible   avia-builder-el-7  el_after_av_textblock  el_before_av_image '><span class='hr-inner ' ><span class='hr-inner-style'><\/span><\/span><\/div><br \/>\n<div  class='avia-image-container  av-styling-    avia-builder-el-8  el_after_av_hr  avia-builder-el-last  avia-align-center '  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\"  ><div class='avia-image-container-inner'><div class='avia-image-overlay-wrap'><img class='avia_image' src='https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg' alt='' title='covid33' height=\"667\" width=\"1000\"  itemprop=\"thumbnailUrl\"  \/><\/div><\/div><\/div><\/p><\/div><div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding   avia-builder-el-9  el_after_av_three_fifth  avia-builder-el-last  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WHO\u2019s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) have finalized a licensing agreement with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody technology. The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine. This represents the [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":15223,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-15222","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-e-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology - International Hospital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology - International Hospital\" \/>\n<meta property=\"og:description\" content=\"WHO\u2019s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) have finalized a licensing agreement with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody technology. The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine. This represents the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"International Hospital\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-15T15:36:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-21T12:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"panglobal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"panglobal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/\"},\"author\":{\"name\":\"panglobal\",\"@id\":\"https:\/\/interhospi.com\/#\/schema\/person\/4689adfa1bdc4ca8bd2efdb65d94fac1\"},\"headline\":\"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology\",\"datePublished\":\"2021-12-15T15:36:10+00:00\",\"dateModified\":\"2021-12-21T12:27:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/\"},\"wordCount\":1248,\"publisher\":{\"@id\":\"https:\/\/interhospi.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg\",\"articleSection\":[\"E-News\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/\",\"url\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/\",\"name\":\"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology - International Hospital\",\"isPartOf\":{\"@id\":\"https:\/\/interhospi.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg\",\"datePublished\":\"2021-12-15T15:36:10+00:00\",\"dateModified\":\"2021-12-21T12:27:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#primaryimage\",\"url\":\"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg\",\"contentUrl\":\"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg\",\"width\":1000,\"height\":667},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/interhospi.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/interhospi.com\/#website\",\"url\":\"https:\/\/interhospi.com\/\",\"name\":\"International Hospital\",\"description\":\"The medical device information portal connecting healthcare professionals to global vendors\",\"publisher\":{\"@id\":\"https:\/\/interhospi.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/interhospi.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/interhospi.com\/#organization\",\"name\":\"International Hospital\",\"url\":\"https:\/\/interhospi.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/interhospi.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2025\/01\/IH-logo.jpg\",\"contentUrl\":\"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2025\/01\/IH-logo.jpg\",\"width\":652,\"height\":188,\"caption\":\"International Hospital\"},\"image\":{\"@id\":\"https:\/\/interhospi.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/interhospi.com\/#\/schema\/person\/4689adfa1bdc4ca8bd2efdb65d94fac1\",\"name\":\"panglobal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/interhospi.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/44754a569744e74e7138c83d1888f5c0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/44754a569744e74e7138c83d1888f5c0?s=96&d=mm&r=g\",\"caption\":\"panglobal\"},\"url\":\"https:\/\/interhospi.com\/author\/panglobal\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology - International Hospital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/","og_locale":"en_GB","og_type":"article","og_title":"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology - International Hospital","og_description":"WHO\u2019s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) have finalized a licensing agreement with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody technology. The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine. This represents the [&hellip;]","og_url":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/","og_site_name":"International Hospital","article_published_time":"2021-12-15T15:36:10+00:00","article_modified_time":"2021-12-21T12:27:11+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg","type":"image\/jpeg"}],"author":"panglobal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"panglobal","Estimated reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#article","isPartOf":{"@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/"},"author":{"name":"panglobal","@id":"https:\/\/interhospi.com\/#\/schema\/person\/4689adfa1bdc4ca8bd2efdb65d94fac1"},"headline":"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology","datePublished":"2021-12-15T15:36:10+00:00","dateModified":"2021-12-21T12:27:11+00:00","mainEntityOfPage":{"@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/"},"wordCount":1248,"publisher":{"@id":"https:\/\/interhospi.com\/#organization"},"image":{"@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg","articleSection":["E-News"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/","url":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/","name":"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology - International Hospital","isPartOf":{"@id":"https:\/\/interhospi.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#primaryimage"},"image":{"@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg","datePublished":"2021-12-15T15:36:10+00:00","dateModified":"2021-12-21T12:27:11+00:00","breadcrumb":{"@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#primaryimage","url":"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg","contentUrl":"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2021\/12\/covid33.jpg","width":1000,"height":667},{"@type":"BreadcrumbList","@id":"https:\/\/interhospi.com\/who-mpp-announce-first-global-non-exclusive-licence-for-a-covid-19-serological-antibody-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/interhospi.com\/"},{"@type":"ListItem","position":2,"name":"WHO, MPP announce first global, non-exclusive licence for a COVID-19 serological antibody technology"}]},{"@type":"WebSite","@id":"https:\/\/interhospi.com\/#website","url":"https:\/\/interhospi.com\/","name":"International Hospital","description":"The medical device information portal connecting healthcare professionals to global vendors","publisher":{"@id":"https:\/\/interhospi.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/interhospi.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/interhospi.com\/#organization","name":"International Hospital","url":"https:\/\/interhospi.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/interhospi.com\/#\/schema\/logo\/image\/","url":"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2025\/01\/IH-logo.jpg","contentUrl":"https:\/\/interhospi.com\/wp-content\/uploads\/sites\/3\/2025\/01\/IH-logo.jpg","width":652,"height":188,"caption":"International Hospital"},"image":{"@id":"https:\/\/interhospi.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/interhospi.com\/#\/schema\/person\/4689adfa1bdc4ca8bd2efdb65d94fac1","name":"panglobal","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/interhospi.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/44754a569744e74e7138c83d1888f5c0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/44754a569744e74e7138c83d1888f5c0?s=96&d=mm&r=g","caption":"panglobal"},"url":"https:\/\/interhospi.com\/author\/panglobal\/"}]}},"_links":{"self":[{"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/posts\/15222"}],"collection":[{"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/comments?post=15222"}],"version-history":[{"count":3,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/posts\/15222\/revisions"}],"predecessor-version":[{"id":15324,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/posts\/15222\/revisions\/15324"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/media\/15223"}],"wp:attachment":[{"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/media?parent=15222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/categories?post=15222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/interhospi.com\/wp-json\/wp\/v2\/tags?post=15222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}